Aspartyl-alanyl-diketopiperazine

N/A

Report date: 2022/12/08 20:00:49
NME

Base Information

Drug NameAspartyl-alanyl-diketopiperazine
Drug Alias NameAmpionDA-DKPDM-9523DMI-9523
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Chronic Knee PainOsteoarthritis, Knee +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmpio
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmpio Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Chronic Knee PainOsteoarthritis, Knee +[5] 

Other Information

ATC CodeN/A
Related LinksN/A